British Journal of Pharmacology
March 2007
R G Pertwee, A Thomas, L A Stevenson et al.
To follow up in vitro evidence that Delta(9)-tetrahydrocannabivarin extracted from cannabis (eDelta(9)-THCV) is a CB(1) receptor antagonist by establishing whether synthetic Delta(9)-tetrahydrocannabivarin (O-4394) and Delta(8)-tetrahydrocannabivarin (O-4395) behave as CB(1) antagonists in vivo. O-4394 and O-4395 were compared with eDelta(9)-THCV as displacers of [(3)H]-CP55940 from specific...
European Journal of Pharmacology
August 21, 1998
J L Wiley, W J Ryan, R K Razdan et al.
Arachidonylethanolamide (anandamide), an endogenous ligand for the cannabinoid receptor, binds competitively to brain cannabinoid receptors and shares many, but not all, of the in vivo effects of delta9-tetrahydrocannabinol. In this study, the cannabinoid effects of anandamide analogs in which the anandamide molecule was altered were assessed in a drug discrimination model. Structural...
Pharmacology, Biochemistry, and Behavior
December 1997
J L Wiley, K M Golden, W J Ryan et al.
In previous research arachidonylethanolamide (anandamide) has been shown to produce behavioral effects in mice characteristic of psychoactive cannabinoids, including antinociception, catalepsy, hypothermia, and hypomotility. However, differences have also been found between anandamide and delta9-tetrahydrocannabinol (delta9-THC), with anandamide having lower potency, a more rapid onset, and...
Journal of Medicinal Chemistry
January 19, 1996
B F Thomas, I B Adams, S W Mascarella et al.
Anandamides are endogenous fatty acid ethanolamides that have been shown to bind to the cannabinoid receptor and possess cannabimimetic activity yet are structurally dissimilar from the classical cannabinoids found in Cannabis sativa. We have employed molecular dynamics studies of a variety of anandamides to characterize their conformational mobility and determine whether there are...
Neuropharmacology
1996
J L Wiley, D R Compton, P M Gordon et al.
delta 8-Tetrahydrocannabinol (delta 8-THC) is a naturally occurring cannabinoid with a characteristic pharmacological profile of in vivo effects. Previous studies have shown that modification of the structure of delta 8-THC by inclusion of a nitrogen-containing functional group alters this profile and may alkylate the cannabinoid receptor, similar to the manner in which beta-funaltrexamine...
Drug and Alcohol Dependence
March 1995
B R Martin, D R Compton, W R Prescott et al.
The basic premise underlying the cannabinoid pharmacophore is that at least three functional groups are involved in the interaction between the ligand and the receptor and that these functional groups in delta 9-THC comprise (a) C11, (b) the phenolic hydroxyl, and (c) the side chain. In order to assess the relative importance of the C11 position and the side chain, a series of C11 substituted...
Pharmacology, Biochemistry, and Behavior
July 1984
B R Martin, M J Kallman, G F Kaempf et al.
The pharmacological potency of R- and S-3'-hydroxy-delta 9-tetrahydrocannabinol (THC) was compared to that of delta 9-THC as well as R/S-3'-OH-delta 9-THC. The S-isomer was found to be considerably more potent than the R-isomer in producing hypoactivity in mice, static-ataxia in dogs, and in generalization testing in rats trained to discriminate delta 9-THC from vehicle. S-3'-OH-delta 9-THC was...